JPMorgan analyst Lisa Gill raised the firm’s price target on Privia Health (PRVA) to $28 from $27 and keeps an Overweight rating on the shares. The analyst updated the company’s model.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA: